Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma

Journal of Clinical Oncology

Volumn 18, Issue 9, 2000, Pages 1928-1935

  Motzer, Robert J ^a   Mazumdar, Madhu ^a   Bacik, Jennifer ^a   Russo, Paul ^a   Berg, William J ^a   Metz, Erica M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BISANTRENE; CYTOKINE; DIDEMNIN B; FLUTAMIDE; INTERLEUKIN 2; N METHYLFORMAMIDE; TOPOTECAN; VINDESINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0034113335     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.9.1928     Document Type: Article

References (43)

1. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
2. Vogelzang NJ, Stadler WM: Kidney cancer. Lancet 352:1691-1696, 1998
3. Figlin RA: Renal cell carcinoma: Management of advanced disease. J Urol 161:381-387, 1999
4. Bukowski R. Immunotherapy in renal cell carcinoma. Oncology (Huntingt) 13:801-813, 1999
5. Pyrhonen S, Salminen E, Ruutu M, et al: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17:2859-2867, 1999
6. Medical Research Council and Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: Karly results of a randomised controlled trial. Lancet 353:14-17, 1999
7. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
8. Minasian LM, Motzer RJ, Gluck L, et al: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993
9. Wong PP, Yagoda A, Currie VE, et al: Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma. Cancer Treat Rep 61:1727-1729, 1977
10. Zeffren J, Yagoda A, Watson RC, et al: Phase II trial of methyl-GAG in advanced renal cancer. Cancer Treat Rep 65:525-527, 1981
11. Ahmed T, Benedetto P, Yagoda A. et al: Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma: Observations obtained in phase II trial of flutamide. Cancer 54:477-481, 1984
12. Benedetto P, Ahmed T, Needles B, et al: Phase II trial of 4′epi-adriamycin for advanced hypernephroma. Am J Clin Oncol 6:553-554, 1983
13. Scher HI, Yagoda A, Ahmed T, et al: Phase II trial of 10-deazaaminopterin for advanced hypernephroma. Anticancer Res 4:409-410, 1984
14. Scher H, Schwartz S, Yagoda A, et al: Phase II trial of bisantrene for advanced hypernephroma. Cancer Treat Rep 66:1653-1655, 1982
15. Scher HI, Yagoda A, Ahmed T. et al: Phase II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma. Cancer Chemother Pnarmacol 14:79-80, 1985
16. Sternberg CN, Yagoda A, Scher HI, et al: Phase II trial of N-methylformamide for advanced renal cell carcinoma. Cancer Treat Rep 70:681-682, 1986
17. Sternberg CN, Yagoda A, Casper E, et al: Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast. Anticancer Res 5:415-417, 1985
18. Sternberg CN, Yagoda A, Scher H, et al: Phase II trial of trimetrexate in patients with advanced renal cell carcinoma: Clinical Community Oncology Program. Eur J Cancer Clin Oncol 25:753-754, 1989
19. Law TM, Motzer RJ, Mazumdar M, et al: Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76:824-832, 1995
20. Motzer RJ, Schwarte L, Murray Law T, et al: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13:1950-1957, 1995
21. Motzer RJ, Scher H, Bajorin D, et al: Phase II trial of didemnin B in patients with advanced renal cell carcinoma. Invest New Drugs 8:391-392, 1990
22. Ilson DH, Motzer RJ, Kradin RL, et al: A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 10:1124-1130, 1992
23. Motzer RJ, Nanus DM, O'Moore P, et al: Phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 52:5775-5779, 1992
24. Motzer RJ, Lyn P, Fischer P, et al: Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13:1958-1965, 1995
25. Law TM, Ilson DH, Motzer RJ: Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 12:143-145, 1994
26. Law TM, Mencel P, Motzer RJ: Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs 12:323-325, 1994
27. Motzer RJ, Murphy BA, Mazumdar M, et al: Randomized phase III trial of interferon alfa-2a (IFN) versus IFN plus 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 18:330a, 1999 (abstr 1271)
28. Berg WJ, Schwartz LH, Amsterdam A, et al: A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 15:353-355, 1997
29. Orrell DH: Albumin as an aid to the interpretation of serum calcium. Clin Chim Acta 35:483, 1971 (abstr)
30. Steineck G, Strander H, Carbin BE, et al: Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: A randomized trial. Acta Oncol 29:155-162, 1990
31. Kriegmar M, Oberneder R, Hofstetter A: Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45:758-762, 1998
32. Henriksson R, Nilsson S, Wersal P, et al: Survival in renal cell carcinoma: A randomized evaluation of tamoxifen vs interleukin-2, alpha interferon (leucocyte) and tamoxifen. Br J Cancer 77:1311-1317, 1998
33. Kirchner H, Buer J, Probst-Kepper M, et al: Risk and long-term outcome in metastatic renal cell carcinoma patients receiving SC interleukin-2, SC interferon-alfa2a and IV 5-fluoruracil. Proc Am Soc Clin Oncol 17:310a, 1998 (abstr 1195)
34. Fossa SD, Kramer A, Droz JP: Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A:1310-1314, 1994
35. Palmer PA, Vinke J, Philip T. et al: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3:475-480, 1992
36. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310-7313, 1988
37. Robertson CN, Linehan WM, Pass HI, et al: Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 144:614-618, 1990
38. Rackley RR, Klein EA, Novick AD: Morbidity and mortality of primary adjuvant nephrectomy in immunotherapy for renal cell carcinoma. J Urol 145:422A, 1991 (abstr)
39. Bennett RT, Lerner SE, Taub HC, et al: Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 154:32-34, 1995
40. Fleischmann JD, Kim B: Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 145:938-941, 1991
41. Rackley R, Novick A, Klein E, et al: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 152:1399-1403, 1994
42. Walther MM, Yang JC, Pass HI, et al: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158:1675-1678, 1997
43. Franklin JR, Figlin R, Rauch J, et al: Cytoreductive surgery in the management of metastatic renal cell carcinoma: The UCLA experience. Semin Urol 14:230-236, 1996